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Abstract Transgenic mice expressing a human mutant a-
galactosidase with an R301Q substitution, which was found in 
a patient with a variant form of Fabry disease, were established. 
The mice transcribed a sufficient amount of a-galactosidase 
mRNA, but the steady-state levels of the enzyme protein were 
decreased in liver, kidney and heart, only residual activity being 
detected in these tissues. The mice will be useful for the 
clarification of the defective regulation of the structurally altered 
enzyme protein expressed by the mutant gene at the organ or 
individual level as well as for the evaluation of drugs that 
stabilize and/or activate the mutant a-galactosidase. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Fabry disease is an X-linked genetic disorder resulting from 
decreased activity of a-galactosidase (EC 3.2.1.22) [1]. In clas-
sical Fabry disease, deficient a-galactosidase activity results in 
the progressive accumulation of ceramide trihexoside and 
causes systemic manifestations, including renal and cardiovas-
cular disorders. Recently, atypical Fabry variants with resid-
ual enzyme activity and cardiomyopathy of late onset were 
reported [2,3], and a screening study revealed that these var-
iants were found in 3 % of unrelated male patients with left 
ventricular hypertrophy referred to a cardiology clinic in Ja-
pan [4]. The incidence of the variant Fabry disease seems to be 
unexpectedly high, and clarification of the pathogenesis 
underlying the variant Fabry disease is very important . 
The R301Q ( C G A ^ C A A ) substitution is one of the gene 
mutat ions found in patients with variant Fabry disease [2]. A 
male patient carrying the R301Q mutat ion developed chest 
pain at the age of 52 years, and hypertrophy of both the 
ventricular septum and the left ventricle was found by electro-
cardiographic and echocardiographic analysis. Biopsy of the 
left ventricular endocardium revealed numerous lamellar in-
clusions in myocardium electron microscopically. The leuko-
cyte a-galactosidase activity of the patient was 4% of the 
normal control level. 
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In this report , we generated and characterized transgenic 
mice expressing a human mutant a-galactosidase with the 
R301Q substitution. 
2. Materials and methods 
2.1. Generation of transgenic mice 
a-Galactosidase cDNA was obtained from cultured lymphoblast 
poly(A)+ RNA by means of reverse transcription/polymerase chain 
reaction (PCR) [5]. cDNA encoding human normal a-galactosidase or 
mutant a-galactosidase with the R301Q substitution was inserted into 
vector pCXN2 (supplied by Dr. J. Miyazaki, Tohoku University, 
Japan), as described previously [6], The constructs were digested 
with Ndel (New England BioLabs, Beverly, MA, USA), and a 3-
kbp DNA fragment including the chicken ß-actin promoter and hu-
man a-galactosidase cDNAs was obtained, and purified by means of 
the cesium chloride method. The standard microinjection method [7] 
was used to introduce the transgenic constructs into pronuclei of 
fertilized eggs from superovulated C57BL/6CrSlc female mice. The 
zygotes were implanted in pseudo-pregnant female Slc:ICR mice. An-
imal experiments were performed according to local institutional 
guidelines for the care and use of laboratory animals. 
2.2. Screening of transgenic mice expressing human a-galactosidase 
The resulting mice were screened for the presence of the transgene 
by means of PCR [8] of DNA. Genomic DNA was prepared from 
punched ear tissue by the standard method [9], and PCR was per-
formed using a pair of primers (5'-TGAGAATTCGTATCTTG-
GACTGGACATCT-3' and 5'-GCCGAATTCTTAAAGTAAGTCT-
TTTAATGAC-3') to amplify a DNA fragment including a partial 
human a-galactosidase cDNA sequence (cDNA #722-1290) in mouse 
genomic DNA. The PCR comprised 30 cycles, each cycle consisting of 
denaturation at 95°C for 1 min, annealing at 55°C for 1 min, and 
extension at 75°C for 1 min. 
2.3. Preparation of genomic DNA and poly(A)+ RNA 
Genomic DNA was isolated from liver tissue, as described above. 
Total RNA was isolated from liver, kidney and heart by the guanidine 
isothiocyanate method [9], and poly(A)+ RNA was purified with oli-
go(dT)-Latex beads (Nippon Roche, Tokyo, Japan). 
2.4. Southern blot analysis 
Genomic DNA (10 (ig) was digested with PvuW (New England 
BioLabs), electrophoresed on a 1% agarose gel, transferred to a nitro-
cellulose membrane, and then hybridization was performed. A PvuW 
fragment of human a-galactosidase cDNA (cDNA #7-827) was 32P-
labeled, as described previously [2], and used as a probe. 
2.5. Northern blot analysis 
One microgram of poly(A)+ RNA from liver, kidney and heart was 
separated by electrophoresis on a 1% agarose gel containing form-
aldehyde, transferred to a nitrocellulose membrane, and then hybri-
dized with 32P-labeled full-length human a-galactosidase cDNA as a 
probe, as described previously [2]. The filter was rehybridized with 
32P-labeled human ß-actin cDNA (Nippon Gene, Tokyo, Japan) to 
determine the quality and quantity of samples. 
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2.6. Western blot analysis 
Tissue homogenates of liver, kidney and heart were centrifuged at 
6000 X g for 10 min at 4°C, and the resultant supernatants were used 
as samples. The samples (liver, 3 ug protein; kidney, 22 ug protein; 
and heart, 9 ug protein) were subjected to sodium dodecylsulfate 
(SDS)-polyacrylamide gel electrophoresis on a 5-20% gradient gel 
under reducing conditions, using Laemmli's system [10]. Then, the 
proteins were transferred to an Immobilon membrane (Millipore, 
Bedford, MA, USA). The membrane was reacted with a rabbit anti-
human a-galactosidase antibody [11] for 1 h at room temperature, 
and then incubated with horseradish peroxidase-conjugated donkey 
anti-rabbit IgG antiserum (Amersham, Buckinghamshire, UK). The 
detection of the reacted protein was performed using enhanced chem-
iluminescence (Amersham) according to the manufacturer's method. 
2.7. Assaying of a-galactosidase activity 
a-Galactosidase activity was determined using the supernatants of 
tissue homogenates with 4-methylumbelliferyl a-D-galactopyranoside 
(Nacalai Tesque, Kyoto, Japan) as a substrate [12]. The amount of 
protein was determined by means of a Bio-Rad dye-binding assay 
(Bio-Rad, Hercules, CA, USA), using bovine serum albumin as a 
standard. 
3. Results 
In this study, we have screened and assessed the presence of 
a transgene as a 587-bp PCR product (data not shown). 
Two mouse lines were obtained, one with a transgene of 
mutant a-galactosidase and the other with one of normal 
a-galactosidase. They were designated C57BL/6CrSlc-TgN 
(GLAR301Q)1962Rin and C57BL/6CrSlc-TgN(GLA)1953-
Rin, respectively (abbreviated as TgN(GLAR301Q)1962 and 
TgN(GLA)1953, respectively). 
The transgene carrier status was also confirmed by South-
ern blotting using liver DNAs from TgN(GLAR301Q)1962 
and TgN(GLA)1953 (Fig. 1). In this analysis, we used mouse 
genomic DNAs digested with Pvull as samples, and the trans-
gene was detected by hybridization with a labeled Pvull frag-
Fig. 1. Southern blot analysis of transgenic mice. 10 ug of genomic 
DNA from transgenic mice, TgN(GLA)1953 (lane 1) and 
TgN(GLAR301Q) 1962 (lane 2), was digested with Pvull and then 
analyzed. Non-transgenic mouse genomic DNA digested with Pvull 
was used as a negative control (lane 3). One, two or five copies (15 
pg, 30 pg and 75 pg; lanes 4, 5 and 6) of plasmid pCXN2 DNA, 
which contained normal a-galactosidase cDNA, were mixed with 
non-transgenic mouse genomic DNA before Pvull digestion and 
used as positive controls. The existence of the transgene is detected 
as a 0.8-kb band, and a few non-specific bands of larger molecular 
sizes are also found. 
Fig. 2. Northern and Western blot analyses of transgenic mice. A: 
Detection of human a-galactosidase mRNA transcribed in mice on 
Northern blotting with human a-galactosidase cDNA as a probe. 
B: Detection of ß-actin mRNA in mice on Northern blotting with 
human ß-actin cDNA as a probe. C: Detection of the human a-gal-
actosidase protein expressed in mice on Western blotting with an 
anti-human a-galactosidase antibody. Lanes 1-3, TgN(GLA)1953; 
lanes 4-6, TgN(GLAR301Q)1962; lanes 7-9, non-transgenic mice. 
Liver (lanes 1, 4 and 7), kidney (lanes 2, 5 and 8), and heart (lanes 
3, 6 and 9). In Northern blotting of ß-actin, a doublet signal was 
found in the heart tissue. The reason is not clear. It might be due 
to the tissue specificity or the assay system with the probe of human 
origin used here, but not RNA degradation. In Western blotting, 
the expressed human a-galactosidase proteins were detected as 54-
60-kDa bands. The differences in molecular size of the expressed a-
galactosidase may be due to the heterogeneity of the sugar chains 
posttranslationally modified in tissues, because glycopeptidase F 
treatment showed an identical molecular mass for the peptide moi-
ety of the enzyme (data not shown). 
ment of human a-galactosidase cDNA as a probe. Therefore, 
the existence of the transgene was determined as a 0.8-kb 
band on a film, and the dose of the transgene integrated 
was roughly estimated from the density of the corresponding 
band. The results showed that almost the same amount of the 
transgene was integrated into both TgN(GLAR301Q)1962 
and TgN(GLA)1953. 
Northern blot analysis revealed that the transgene was 
highly transcribed in liver and heart, and to a lesser amount 
in kidney (Fig. 2A). The transcript was clearly detected as a 
1.4-kb band on a film, and the size of the transcript was the 
same as that found in cultured human lymphoblasts (data not 
shown). A sufficient amount of human a-galactosidase 
mRNA was transcribed in TgN(GLAR301Q)1962, although 
it was slightly decreased as compared with that in 
TgN(GLA)1953, when estimated from the amount of ß-actin 
mRNA as an internal control (Fig. 2B). 
a-Galactosidase activity in serum, liver, kidney and heart is 
summarized in Table 1. High enzyme activity was found in 
tissues of TgN(GLA)1953 (about 75-510-fold higher than in 
non-transgenic mice). However, the enzyme activity was very 
low in tissues of TgN(GLAR301Q)1962 (only about 2-fold 
higher than in non-transgenic mice, and the enzyme activity 
might be due to the expressed human mutant enzyme besides 
the internal enzyme of the mouse), and there were no differ-
ences in distribution. Western blot analysis showed expressed 
human a-galactosidase proteins, detected as 54-60-kDa 
bands, in tissues of TgN(GLA)1953 (Fig. 2C). However, we 
could not detect any band representing a-galactosidase in 
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Table 1 
a-Galactosidase activity in transgenic mice 
Serum" Liverb Kidneyb Heartb 
TgN(GLA)1953 7082 6100 900 2200 
TgN(GLAR301Q)1962 30 58 22 28 
Non-transgenic mouse 14 26 12 12 
a-Galactosidase activity: anmol/h/ml, bnmol/h/mg protein. 
tissues of TgN(GLAR301Q)1962 on Western blotting under 
the analytical conditions described here (Fig. 2C), although 
there might be a small amount of an expressed product, con-
sidering the results of enzyme assaying. These data suggested 
that the reduced activity of a-galactosidase in tissues of 
TgN(GLAR301Q)1962 mainly resulted from a decreased 
amount of the expressed enzyme protein. 
4. Discussion 
The human a-galactosidase gene is approximately 12 kb 
long and consists of seven exons, and its cDNA encodes a 
precursor peptide of 429 amino acids including a 31-residue 
signal peptide [1]. The mutation, R301Q, was found in the a-
galactosidase gene of a 52-year-old Japanese male Fabry pa-
tient with mild clinical manifestations and residual a-galacto-
sidase activity. 
We prepared transgenic mice expressing a human mutant a-
galactosidase with the R301Q substitution and analyzed them 
biochemically. The transgenic mice transcribed a sufficient 
amount of a-galactosidase mRNA in liver, kidney and heart. 
But the steady-state level of the enzyme protein decreased in 
all of these tissues, although a small amount of the mutant a-
galactosidase with enzymatic activity might exist in the tissues. 
So, a defect of translation or posttranslational abnormality 
might occur in the mouse. 
Previously we tried to characterize the mutation using cul-
tured cells as samples. The a-galactosidase activity in cultured 
lymphoblasts from the patient carrying the R301Q mutation 
was 4% of the normal control level [2,13]. Transient expres-
sion of the mutant a-galactosidase cDNA in COS-1 cells re-
vealed that a sufficient amount of a-galactosidase mRNA was 
transcribed, and low residual enzyme activity was expressed 
[9]. Furthermore, the addition of galactose to the culture me-
dium of lymphoblasts derived from the patient increased the 
a-galactosidase activity significantly [13]. The same effect was 
also found in a mutant, Q279E (CAG->GAG), found in an 
unrelated patient with the variant form of Fabry disease who 
expressed a-galactosidase with normal affinity toward a sub-
strate and with decreased molecular stability [6]. Considering 
the results, such mutant enzymes might be posttranslationally 
degraded, and the development of drugs that stabilize and/or 
activate such enzyme proteins may allow the curing of some 
patients with Fabry disease. 
We conclude that transgenic mice expressing human mutant 
a-galactosidase with the R301Q substitution were established. 
These mice will be useful for research to clarify the defective 
regulation of the structurally altered enzyme protein resulting 
from the mutant gene at the organ or individual level, and 
furthermore for evaluation of drugs that stabilize and/or acti-
vate the mutant enzymes. 
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